2022
Cost‐effectiveness of hepatitis C virus test‐and‐treat and risk reduction strategies among men who have sex with men living with HIV in France
Castry M, Cousien A, Champenois K, Supervie V, Velter A, Ghosn J, Yazdanpanah Y, Paltiel A, Deuffic‐Burban S. Cost‐effectiveness of hepatitis C virus test‐and‐treat and risk reduction strategies among men who have sex with men living with HIV in France. Journal Of The International AIDS Society 2022, 25: e26035. PMID: 36451286, PMCID: PMC9712801, DOI: 10.1002/jia2.26035.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusIncremental cost-effectiveness ratioHigh-risk groupHepatitis C virusHCV screeningRisk reduction strategiesHCV infectionYearly screeningHepatitis C Virus TestRisk reductionHCV screening practicesNew HCV infectionsHigh-risk individualsRisk reduction interventionsCost-effectiveness ratioCost-effective dependingImmunodeficiency virusC virusScreening practicesLifetime horizonScreening frequencyVirus testReduction interventionsRisk behaviorsBehavioral interventions
2020
Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach
Castry M, Cousien A, Supervie V, Velter A, Ghosn J, Paltiel AD, Yazdanpanah Y, Deuffic-Burban S. Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach. Gut 2020, 70: 1561-1569. PMID: 33109688, DOI: 10.1136/gutjnl-2020-321744.Peer-Reviewed Original ResearchConceptsHCV incidenceRisk reduction strategiesHCV epidemicEarly HCV diagnosisHCV natural historyHCV risk behaviorsDrug-related behaviorsEpidemic of HCVHCV cascadeHCV prevalenceDynamic compartmental modelHCV eliminationHCV transmissionHCV diagnosisFrequent screeningWHO targetHIVRisk behaviorsNatural historyMSMCurrent French practicesIncidenceHCVImpact of testEpidemic